# Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina

Source: https://onco.cc/trials/nct03808337/  
OnCo record `nct03808337` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease is a phase 2, randomised interventional study registered as NCT03808337 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 145 participants, started 2019-01-16 and due to reach its primary completion in 2027-01. Interventions recorded: Stereotactic Body Radiotherapy/SBRT; Systemic Therapy/Standard of Care. Conditions listed: Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Metastatic Breast Cancer; Metastatic Non-Small Cell Lung Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT03808337
- Phase: 2
- Setting: PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 145

## Sources

- ClinicalTrials.gov NCT03808337: https://clinicaltrials.gov/study/NCT03808337

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03808337.json